RxDoctor Payments Data

Alyssa Skalitzky

Psychiatric/Mental Health · Kenosha, WINPI 1598906596

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 473 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,864in general payments, 2019–2025

Across 473 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Supernus Pharmaceuticals, Inc.$1K
  • Alkermes, Inc.$1K
  • Johnson & Johnson$970
  • AbbVie$571
  • Axsome Therapeutics, Inc.$536
  • Otsuka America Pharmaceutical, Inc.$443
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$7,66097%
  • Education$2043%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,864 in reported general payments places this provider in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.

See all psychiatric/mental health providers in Wisconsin

Medicare billing

Part B allowed, 2024
$13,183
Medicare patients
38
Services billed
154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$89,269
VraylarCariprazine Hcl58$85,839
Invega SustennaPaliperidone Palmitate25$80,990
Abilify MaintenaAripiprazole21$60,226
RexultiBrexpiprazole29$42,508
BelsomraSuvorexant44$22,959
TrintellixVortioxetine Hydrobromide17$19,902
CaplytaLumateperone Tosylate13$19,834
Paliperidone ErPaliperidone34$15,863
VyvanseLisdexamfetamine Dimesylate39$14,977
Lisdexamfetamine Dimesylate26$5,782
Quetiapine Fumarate162$4,660
Divalproex Sodium ErDivalproex Sodium46$4,383
Aripiprazole32$3,844
Clozapine49$3,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$443$102,73450 claims
Neurocrine Biosciences, Inc.Ingrezza$335$89,26912 claims
AbbVieVraylar$571$85,83958 claims
Johnson & JohnsonInvega Sustenna$970$80,99025 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$337$34,87956 claims
MerckBelsomra$25$22,95944 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$198$19,83413 claims
Lilly USA, LLCOlanzapine$39$1,13047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.

Other psychiatric/mental health in Kenosha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →